In this study, we hypothesize that through the inhibition of RRM2, cyclin D1 and the NF-κB pathway, DDX can significantly halt the growth of ER+ and ER− breast cancer cells along with their PLB-resistant counterparts. This evidence concerns the gene NFKB1 and breast carcinoma.